Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€35.74
-€0.84(-2.38%)
At close: 4:00 PM EDT
€35.74
-€0.84(-2.38%)
Day’s Range― - ―
52-Week Range€8.54 - €47.66
Previous CloseN/A
Volume28.17K
Average Volume (3M)155.94K
Market Cap
€1.53B
Enterprise Value€986.13
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume149,871
30 Day Avg. Volume155,937
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)€20.97M
Bulls Say, Bears Say
Bulls Say
Proprietary Oncology PlatformThe proprietary nanoparticle approach gives Nanobiotix a differentiated scientific platform in oncology, with potential applicability alongside radiotherapy and other treatments. If clinical development succeeds, the technology could support multiple indications and create strategic value beyond a single product.
2025 Revenue ReboundThe sharp 2025 revenue increase indicates that Nanobiotix can generate meaningful collaboration or development-related revenue as programs advance. Although historical revenue has been inconsistent, this growth demonstrates commercial potential and could improve funding capacity if it proves repeatable.
Janssen CollaborationThe Janssen relationship provides an established development and commercialization channel with a larger biopharmaceutical partner. Such collaboration can support program advancement, provide potential milestone and royalty economics, and reduce the burden of independently developing and commercializing NBTXR3.
Bears Say
Clinical-stage Business ModelNanobiotix remains dependent on clinical development and collaboration or licensing outcomes rather than recurring sales from approved therapies. This makes future funding and operating progress more dependent on external capital, partner commitments, and successful clinical or regulatory milestones.
Persistent Cash BurnOngoing operating and free-cash-flow deficits show that current activities consume cash rather than self-fund growth. Because free cash flow broadly tracks net losses, continued research and development will require financing, partnerships, or other capital sources over the next several quarters.
Negative Equity And Rising DebtA persistently negative equity base weakens financial flexibility and makes the capital structure harder to manage. Rising debt adds repayment and financing pressure while losses continue, potentially limiting Nanobiotix’s ability to absorb setbacks or fund development without additional external support.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €8.54 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.53B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 13 days.
How were Nanobiotix SA’s earnings last quarter?
Nanobiotix SA released its earnings results on Mar 31, 2026. The company reported -€0.39 earnings per share for the quarter, beating the consensus estimate of -€0.44 by €0.05.
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Overvalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Nanobiotix SA reported an EPS of -€0.39 in its last earnings report, beating expectations of -€0.44. Following the earnings report the stock price went down -4.002%.
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―